TORONTO, le 10 juin 2019 /CNW/ - Les résultats détaillés de REWIND, l'étude sur l'issue cardiovasculaire portant sur Trulicity ® (dulaglutide), ont montré une réduction significative de 12 ...

TORONTO, le 5 nov. 2018 /CNW/ - Trulicity ® (dulaglutide) a considérablement réduit les événements cardiovasculaires majeurs, paramètre d'évaluation combinant les décès d'origine ...

Eli Lilly annonce que Mounjaro a atteint l'objectif principal d'un essai de phase III en démontrant sa non-infériorité face à ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Diffusé le 25 juillet 2019 Dans cette 26e baladodiffusion, les Drs Luc Lanthier et Gabriel Huard discutent de l’efficacité CV du dulaglutide (Trulicity®) un antihyperglycémiant de la classe des ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Dulaglutide injection should be given subcutaneously in the abdomen, thigh or upper arm once e every week at any time of the day. The initial dose is 0.75 mg once a week.

Dulaglutide injection should be given subcutaneously in the abdomen, thigh or upper arm once e every week at any time of the day. The initial dose is 0.75 mg once a week.